The control of tumour growth by restricting angiogenesis has attracted tremendous attention in recent years. The initial work using anti-angiogenic drugs alone was promising but did not translate into ...

Pulmonary vascular function is impaired with increased pulmonary blood flow (PBF). We hypothesized that a peroxisome proliferator–activated receptor-γ (PPAR-γ) agonist would mitigate this effect. An ...

February 20, 2007 — The US Food and Drug Administration (FDA) has approved a vascular shunt for temporarily restoring blood flow to severely injured limbs, a molecular test to assess the risk for ...

AMSTERDAM, the Netherlands -- Embolization of large spontaneous portosystemic shunts can relieve refractory hepatic encephalopathy and can keep many patients free of it for the long term as long as ...

The U.S. Food and Drug Administration (FDA) today cleared for U.S. marketing a vascular shunt, a medical device that can help save the arms and legs of soldiers critically injured in combat as well as ...

There is a persistent lack of effective treatments for heart failure with preserved ejection fraction (HFpEF), so in this study, investigators examined the impact of an atrial shunt among patients ...

William Crenshaw, M.D., Washington Imaging Services, 1135 116th Ave. NE, Suite 260, Bellevue, 425.688.0100, Overlake Hospital Medical Center; University of Virginia Medical School, 1987; diagnostic ...

One day after the release of the disappointing results from the REDUCE LAP-HF II trial, testing an atrial shunt in heart failure with midrange or preserved ejection fraction (HFmrEF and HFpEF), a ...

BOSTON, MA—This week’s Technology and Heart Failure Therapeutics (THT) 2023 meeting featured more than a dozen talks on interatrial shunts to reduce left atrial pressures and volume overload in heart ...